This 18-minute MrBeast breakdown will teach you more about getting views, growing on YouTube, and going viral than most creators learn in years.
Bookmark it and give it 18 minutes today, no matter what.
This man ran the equities book for George Soros
then became chief investment officer for Steve Cohen
now he runs a $4 billion fund - and just revealed his #1 pick on stage
"Barry Diller owns 26% and just bid for the company - I would not sell my shares to him"
MGM has two hidden assets nobody is pricing in
300,000 square feet of empty casino space in Dubai - waiting for gambling to be legalized
"I think the stock is a triple - could be worth $150"
bookmark and watch the full pitch ↓
The number one issue the US has struggled with in soccer isn’t athleticism, it’s skill. Our passing was the best it has ever been last night against Paraguay. Watch this.
I'm a cardiologist. I've held dying hearts in my hands in the cath lab at 3 AM. And I need to tell you something that changes everything about how we prevent heart attacks.
For decades, the entire field was built on one target: lower LDL cholesterol. Statins save lives — that's settled science. But too many of my patients did everything right — took their statins, hit their numbers, lived clean — and still ended up on my table with a ruptured artery.
We were treating the smoke while the fire kept burning.
The fire is inflammation. And the evidence is now overwhelming.
The CANTOS trial proved it first — lowering inflammation independent of cholesterol reduced cardiac events. But the newer data is what keeps me up at night.
AI-enhanced CT angiography can now detect inflamed arteries by measuring changes in the fat surrounding your coronary vessels — the perivascular fat attenuation index. Higher inflammation in the fat around even one artery independently predicts cardiac death. When multiple arteries show inflammation, the risk multiplies dramatically — even in patients whose cholesterol looks perfect.
This isn't theoretical. This is measurable. Right now. On a scan you can get this month.
Low-dose colchicine — a drug that's been around for centuries for gout — is now FDA-approved specifically for reducing cardiovascular events. It works by quieting the inflammatory cascade that destabilizes the plaque sitting in your arteries. A pill that costs pennies is saving lives the statins couldn't reach.
And the next wave is already in Phase 3 trials. Ziltivekimab — an IL-6 inhibitor — targets the central inflammatory pathway driving atherosclerosis. Phase 2 data showed a 90% reduction in hsCRP. The ZEUS cardiovascular outcomes trial is enrolling now, with results expected late 2026 into 2027. If positive, anti-inflammatory therapy will become standard in managing heart disease alongside lipid-lowering. The era of inflammation-targeted cardiology is arriving.
But it goes deeper than drugs. AI is now predicting heart failure and cardiac events 5+ years before symptoms — integrating CT imaging, electronic health records, and genetic data with accuracy that jumps far beyond traditional risk calculators.
And polygenic risk scores — a simple genetic test that flags inherited cardiovascular risk — are now formally recognized as a risk-enhancing factor in the 2026 ACC/AHA guidelines. A single blood draw can reveal risk that's been silently building since birth. Decades before the first chest pain.
Here's what this means for you right now — today:
Ask your doctor for a high-sensitivity CRP test. It's cheap, routine, and measures the systemic inflammation that standard cholesterol panels completely miss. You can have perfect LDL and inflamed arteries that are quietly preparing to rupture.
If your hsCRP is elevated, discuss low-dose colchicine with your physician. It's FDA-approved for exactly this.
Push for a coronary CT angiography with AI plaque and inflammation analysis if you have risk factors. This isn't the stress test your parents got. This is 3D visualization of your actual arteries — with AI quantifying not just how much plaque you have, but what kind it is and whether the surrounding tissue is inflamed.
Consider polygenic risk score testing — especially with a family history of early heart disease. It's now guideline-supported.
And the foundation that never changes: move daily, eat real food, sleep 7-9 hours, manage stress, and know your numbers — ApoB, Lp(a), hsCRP, fasting insulin.
I left Iran as a child with nothing. I rebuilt everything in a country that gave me the freedom to become a physician. I've spent twenty years watching patients get second chances.
The ones who haunt me aren't the ones who died on my table. They're the ones who survived but never acted on what the science was telling them — years before the event that didn't have to happen.
You can have perfect cholesterol and still have a heart attack. Inflammation plus genetics can drive plaque rupture in arteries that look "fine" on a standard panel.
The myth that normal cholesterol means you're safe has cost more lives than I can count.
We now have the tools to detect the fire — not just the smoke. AI to see it. Genetics to predict it. Drugs to quiet it. And the ancient basics — movement, real food, sleep, purpose — to prevent it from starting.
Prevention is the new cure. And the science to make it real is no longer coming.
It's here.
🇺🇸 Miami's BBQ scene is officially shedding its reputation as a culinary afterthought and evolving into a distinct powerhouse.
Today, the city boasts a unique signature style, packing smoker trays with local flavors like cafecito rubs, guava sauces, and mojo marinades.
Ready to experience this smoke-ring revolution? Here are the top Miami BBQ spots you need to try.
🎥 iviethefoodie | IG
A few ways to think about long duration.
1) Biz creates value over time but non linearly and the stock therefore doesn’t compound linearly either.
2.) Biz creates a lot of value over a relatively short period of time and the stock captures that value creation non linearly.
3.) Biz creates value linearly and the stock more or less mirrors the value creation path.
4.) Biz creates value pretty linearly but stock over and under shoots too much relative to second derivative rates of change.
5.) Biz creates very little value but is sooo cheap it will eventually re rate higher.
IMO only one of these ideas (#3) should have pure duration where the market makes it easy for you to set and forget your position. All the other ones require you to actively add alpha in how you position when the biz value and stock deviate from one another. That’s what I mean when I use the word duration. You can have duration of your opinion without static duration of your position size.